These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 6296361

  • 21. Lack of interaction between cholecystokinin and opioid systems in the central control of breathing.
    Dierssen M, Flórez J, Hurlé MA.
    Rev Esp Fisiol; 1989; 45 Suppl():185-90. PubMed ID: 2641818
    [Abstract] [Full Text] [Related]

  • 22. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
    Saito T, Ukai K, Masuda T, Nakagawa T, Kimura K, Fujii M, Wakatsuki K, Saeki M, Kasai H.
    Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
    [Abstract] [Full Text] [Related]

  • 23. Effects of cholecystokinin, caerulein and pentagastrin on arterial blood pressure and plasma renin activity in rats.
    Wiśniewska RJ.
    Pol J Pharmacol; 1997 Dec; 49(6):419-23. PubMed ID: 9566045
    [Abstract] [Full Text] [Related]

  • 24. Cardiovascular and respiratory responses to a panicogenic agent in anaesthetised female Wistar rats at different stages of the oestrous cycle.
    Brack KE, Jeffery SM, Lovick TA.
    Eur J Neurosci; 2006 Jun; 23(12):3309-18. PubMed ID: 16820020
    [Abstract] [Full Text] [Related]

  • 25. Hypotensive effect of urapidil: CNS site and relative contribution.
    Gillis RA, Dretchen KL, Namath I, Anastasi N, Dias Souza J, Hill K, Browne RK, Quest JA.
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):103-9. PubMed ID: 2434784
    [Abstract] [Full Text] [Related]

  • 26. Exocrine effects of the CCK antagonist L-364,718 in canine pancreatic autografts.
    Garvin PJ, Niehoff ML, Burton FR, Dysarz FA, Meadow R, Solomon H.
    J Surg Res; 1996 Feb 15; 61(1):256-9. PubMed ID: 8769975
    [Abstract] [Full Text] [Related]

  • 27. Comparison of the effects of cholecystokinin and cholecystokinin octapeptide on pancreatic secretion, gallbladder contraction, and plasma pancreatic polypeptide in man.
    Regan PT, Go VL, DiMagno EP.
    J Lab Clin Med; 1980 Oct 15; 96(4):743-8. PubMed ID: 7419959
    [Abstract] [Full Text] [Related]

  • 28. Cholecystokinin octapeptide and gastric mechanoreceptor activity in rat brain.
    Ewart WR, Wingate DL.
    Am J Physiol; 1983 Jun 15; 244(6):G613-7. PubMed ID: 6305211
    [Abstract] [Full Text] [Related]

  • 29. Stimulation of growth of azaserine-induced putative preneoplastic lesions in rat pancreas is mediated specifically by way of cholecystokinin-A receptors.
    Povoski SP, Zhou W, Longnecker DS, Roebuck BD, Bell RH.
    Cancer Res; 1993 Sep 01; 53(17):3925-9. PubMed ID: 8358719
    [Abstract] [Full Text] [Related]

  • 30. Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.
    Konturek JW.
    J Physiol Pharmacol; 1994 Dec 01; 45(4 Suppl 1):3-66. PubMed ID: 7787215
    [Abstract] [Full Text] [Related]

  • 31. Respiratory actions induced by cholecystokinin at the brainstem level.
    Hurlé MA, Dierssen MM, Morin-Surun MP, Oceja C, Flórez J.
    Peptides; 1988 Dec 01; 9(4):809-15. PubMed ID: 3226957
    [Abstract] [Full Text] [Related]

  • 32. Atropine and naloxone block the colonic contraction elicited by cholecystokinin and pentagastrin.
    Hellström PM.
    Acta Physiol Scand; 1985 May 01; 124(1):25-33. PubMed ID: 4013785
    [Abstract] [Full Text] [Related]

  • 33. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs.
    Ninomiya K, Saito T, Wakatsuki K, Saeki M, Kato T, Kasai H, Kimura K, Fujii M.
    Arzneimittelforschung; 1998 Jan 01; 48(1):52-4. PubMed ID: 9522032
    [Abstract] [Full Text] [Related]

  • 34. Drug interaction with gamma-aminobutyric acid/benzodiazepine receptors at the ventral surface of the medulla results in pronounced changes in cardiorespiratory activity.
    Gillis RA, Namath IJ, Easington C, Abrahams TP, Guidotti A, Quest JA, Hamosh P, Taveira da Silva AM.
    J Pharmacol Exp Ther; 1989 Feb 01; 248(2):863-70. PubMed ID: 2537419
    [Abstract] [Full Text] [Related]

  • 35. The influence of C-terminal cholecystokinin fragments in the circulatory system of rats.
    Wiśniewska RJ, Kupryszewski G.
    Pol J Pharmacol Pharm; 1992 Feb 01; 44(3):281-7. PubMed ID: 1470565
    [Abstract] [Full Text] [Related]

  • 36. The effect of centrally administered erythropoietin on cardiovascular and respiratory system of anaesthetized rats.
    Yalcin M, Ak F, Cangul IT, Erturk M.
    Auton Neurosci; 2007 Jul 31; 134(1-2):1-7. PubMed ID: 17306629
    [Abstract] [Full Text] [Related]

  • 37. Interaction of cholecystokinin (CCK-33) and its C-terminal fragments: CCK-8 and CCK-4 with alpha- and beta-adrenoceptor agonists and antagonists in the cardiovascular system of diabetic rats. Part B.
    Wiśniewska RJ.
    Pol J Pharmacol; 1998 Jul 31; 50(3):213-23. PubMed ID: 9861629
    [Abstract] [Full Text] [Related]

  • 38. Different targets involved in the effect of cholecystokinin on respiration.
    Hurlé M, Morin-Surun MP, Foutz AS, Boudinot E, Denavit-Saubié M.
    Eur J Pharmacol; 1985 Nov 26; 118(1-2):87-96. PubMed ID: 4085552
    [Abstract] [Full Text] [Related]

  • 39. Differential contribution of cholecystokinin receptors to stress-induced modulation of seizure and nociception thresholds in mice.
    Homayoun H, Dehpour AR.
    Pharmacol Biochem Behav; 2004 Jun 26; 78(2):209-15. PubMed ID: 15219760
    [Abstract] [Full Text] [Related]

  • 40. Cholecystokinin-induced satiety is mediated through interdependent cooperation of CCK-A and 5-HT3 receptors.
    Hayes MR, Savastano DM, Covasa M.
    Physiol Behav; 2004 Sep 30; 82(4):663-9. PubMed ID: 15327914
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.